Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Inmunotek is a research-based pharmaceutical company specializing in the diagnosis and treatment of diseases in the fields of allergy and immunology. Headquartered in Spain with operations in New Zealand, the company designs, manufactures, and markets advanced immunotherapy products, including personalized allergy vaccines and bacterial preparations. Their core product portfolio includes Oraltek (sublingual spray), Alunext (subcutaneous immunotherapy), and Bactek (bacterial vaccines) for respiratory and urinary tract infections. Inmunotek maintains a strong focus on R&D, utilizing proprietary technology to develop next-generation adjuvants and delivery systems for immunomodulation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Inmunotek New Zealand.